Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/James Vane
JEF

James Vane

Wall Street Analyst
β˜…β˜…β˜…β˜…β˜…
#283
on 13Foresight Β· ranked by our own returns
66%
Success Rate
+8.2%
Average Return
51 of 77 calls profitable Β· +3.8% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 66% of James Vane's ratings turned a profit when each position was held for 1 year β€” averaging +8.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

45 Buy 32 Hold 8 Sell
James's Stock Coverage 38 ratings Β· 2026-11-19
Company Date Position Consensus β“˜ Price Target β“˜ 1-Yr Return vs S&P 500 β“˜
DE:GXI
Gerresheimer
Oct 30, 2026 HOLD Hold
+90.8% avg upside
16 analysts
$26.80
16.44% Downside
-4.7% Β·
FR:DIM
Sartorius Stedim Biotech
Oct 29, 2026 BUY Strong Buy
+19.8% avg upside
12 analysts
$266.00
19.16% Upside
-0.1% Β·
DE:SRT3
Sartorius
Oct 29, 2026 BUY Strong Buy
-0.2% avg upside
19 analysts
$315.00
7.89% Upside
-0.4% Β·
DE:SRT
Sartorius
Oct 29, 2026 BUY Strong Buy
+64.4% avg upside
5 analysts
$253.00
10.57% Upside
-1.1% Β·
GB:OXB
Oxford BioMedica
Oct 26, 2026 BUY Strong Buy
+31.5% avg upside
5 analysts
$827.00
53.43% Upside
+0.6% Β·
DE:FRE
Fresenius SE & Co. KGaA
Oct 21, 2026 BUY Strong Buy
+8.5% avg upside
21 analysts
$55.00
15.04% Upside
+18.4% Β·
DE:MRK
Merck KGaA
Oct 19, 2026 HOLD Buy
-7.2% avg upside
34 analysts
$144.00
4.92% Downside
+2.2% Β·
GB:HIK
Hikma Pharmaceuticals
Sep 25, 2026 BUY Buy
+38.9% avg upside
9 analysts
$2025.00
17.00% Upside
+5.3% Β·
GB:CVSG
CVS Group plc
Sep 25, 2026 HOLD Buy
+15.6% avg upside
4 analysts
$1400.00
5.59% Upside
+12.5% Β·
CH:SDZ
Sandoz Group Ltd
Sep 10, 2026 BUY Buy
-14.9% avg upside
12 analysts
$94.00
14.05% Upside
+26.8% Β·
IT:1SXP
SCHOTT Pharma AG & Co. KGaA
Aug 12, 2026 HOLD Buy
-12.6% avg upside
6 analysts
$17.30
31.02% Downside
+24.1% Β·
DE:FME
Fresenius Medical Care AG & Co. KGaA
Aug 11, 2026 SELL Hold
+22.7% avg upside
24 analysts
$30.00
25.64% Downside
+2.2% Β·
RGEDF
Chemical Works of Gedeon Richter
Aug 11, 2026 BUY Strong Buy
+2.0% avg upside
3 analysts
$44.95
15.92% Upside
+0.3% Β·
FR:VIRP
Virbac SA
Jul 31, 2026 HOLD Buy
+3.4% avg upside
4 analysts
$360.00
3.75% Upside
+5.6% Β·
CH:LONN
Lonza Group Ltd
Jul 28, 2026 BUY Strong Buy
+1.2% avg upside
21 analysts
$781.00
21.14% Upside
+15.9% Β·
PL:DIA
Diagnostyka S.A.
Jul 13, 2026 HOLD Hold
+18.6% avg upside
1 analyst
$176.00
18.61% Upside
-13.5% Β·
CH:SFZN
Siegfried Holding AG
May 13, 2026 HOLD Buy
+28.1% avg upside
4 analysts
$88.00
22.59% Upside
-11.0% Β·
ES:ROVI
Laboratorios Farmaceuticos Rovi
May 13, 2026 HOLD Hold
+2.6% avg upside
1 analyst
$64.20
2.65% Upside
+19.2% Β·
CH:NOVN
Novartis AG
Apr 28, 2026 HOLD Buy
-15.0% avg upside
32 analysts
$110.00
17.79% Downside
+7.7% Β·
NL:PHIA
Koninklijke Philips N.V.
Jan 16, 2026 HOLD Buy
+24.3% avg upside
21 analysts
β€” +16.3% Β·
CH:BANB
Bachem Holding AG
Sep 25, 2025 SELL Sell
-9.7% avg upside
4 analysts
$49.30
41.25% Downside
-42.7% Β·
GB:SPI
Spire Healthcare
Aug 15, 2025 BUY Strong Buy
+14.9% avg upside
6 analysts
$298.00
19.72% Upside
+5.9% Β·
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
Aug 11, 2025 BUY Buy
-2.2% avg upside
9 analysts
$61.50
16.04% Upside
+7.5% Β·
INDV
Indivior
Feb 25, 2025 BUY Strong Buy
+1.0% avg upside
10 analysts
$13.06
63.15% Downside
+307.1% Β·
FMS
Fresenius Medical Care
Aug 08, 2024 SELL Hold
+79.0% avg upside
15 analysts
$17.50
22.20% Downside
-35.6% Β·
FSNUY
Fresenius SE & Co
May 14, 2024 BUY Strong Buy
-20.4% avg upside
7 analysts
$11.00
17.51% Downside
+50.1% Β·
FR:CLARI
Clariane
Jan 05, 2024 HOLD Buy
+562.4% avg upside
6 analysts
$4.49
40.46% Upside
-16.2% Β·
DE:SHL
Siemens Healthineers AG
Nov 08, 2023 HOLD Buy
+14.8% avg upside
24 analysts
$49.00
14.24% Upside
+10.1% Β·
CH:STMN
Straumann Holding AG
Feb 23, 2023 BUY Strong Buy
+32.7% avg upside
15 analysts
$148.00
51.83% Upside
+15.9% Β·
GB:CTEC
ConvaTec
Nov 22, 2022 BUY Strong Buy
+22.0% avg upside
18 analysts
$300.00
22.78% Upside
-2.1% Β·
GB:0QBO
Coloplast A/S
Feb 08, 2022 BUY Buy
+50.9% avg upside
17 analysts
$1150.00
138.40% Upside
-9.7% Β·
FR:EMEIS
Orpea SA
Jan 28, 2022 HOLD Buy
+710.1% avg upside
6 analysts
$43.00
331.19% Upside
Β· Β·
GB:0M2O
Orion Corporation
Aug 27, 2021 SELL Strong Sell
-68.1% avg upside
3 analysts
$28.70
71.27% Downside
-43.5% Β·
GB:0GZK
Ion Beam Applications SA IBA
Jan 20, 2020 SELL Strong Sell
-26.0% avg upside
2 analysts
β€” -14.2% Β·
APNHY
Aspen Pharmacare
Dec 05, 2019 HOLD Hold
2 analysts
β€” +10.5% Β·
SE:MCOV.B
Medicover AB
Nov 01, 2018 BUY Strong Buy
-67.2% avg upside
1 analyst
$93.00
67.23% Downside
Β· Β·
RDY
Dr Reddy's Laboratories
Nov 01, 2017 SELL Sell
+67.2% avg upside
3 analysts
$30.50
115.15% Upside
+5.8% Β·
HKMPY
Hikma Pharmaceuticals
Aug 21, 2017 HOLD Buy
3 analysts
β€” +33.7% Β·
πŸ”’ 33 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
James Vane β€” Frequently Asked Questions
How accurate are James Vane's stock ratings?
Based on the calls 13Foresight could measure, about 66% of James's ratings were profitable over a one-year hold, with an average return of +8.2% per rating, or +3.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is James ranked on 13Foresight?
James Vane is currently ranked #283 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on DE:GXI, FR:DIM, DE:SRT3, DE:SRT, GB:OXB, DE:FRE, DE:MRK, GB:HIK, GB:CVSG, CH:SDZ, IT:1SXP, DE:FME and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.